undamentalytics Newsletter
Sign in

Amylyx Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2025, Amylyx Pharmaceuticals, Inc. had return on equity of -61.6%, debt equal to 0.0% of equity and a current ratio of 14.27. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Gross margin—86.5%93.3%93.2%—
Operating margin<−999%−905.7%10.2%−360.2%—
Net margin<−999%−892.4%12.9%−345.4%—
Free-cash-flow margin<−999%−820.5%2.8%−192.1%—
Return on equity——12.7%−100.9%−61.6%
Return on assets−83.3%−79.8%10.8%−84.9%−55.0%
Asset turnover0.000.090.840.25—
Current ratio6.038.205.666.6714.27
Debt to equity—0.0%0.0%0.0%0.0%
Effective tax rate——9.3%——
R&D as % of revenue>999%420.4%33.7%119.1%—
SG&A as % of revenue>999%571.9%49.5%130.9%—
Capital spending as % of revenue123.9%11.4%0.3%0.2%—
Free cash flow ÷ net income——21.7%——

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amylyx Pharmaceuticals, Inc.